суббота, 30 августа 2014 г.

Human Capital ROI: Definition, Formula, and Calculation


Posted by Erik van Vulpen

Whether you’re at a dinner table or at a board meeting, the big “V’ word is inevitably brought up when it comes to the topic of Human Capital. In other words, what value does human capital create? After decades of research and debate, there is finally a way to substantially show the value that human capital adds through measuring human capital return on investment (human capital ROI). Advances in good data practices, measurements, and metrics have been able to demonstrate the value of human capital efforts. 

Human capital as a function exists to recruit, develop and retain the very best talent. By this logic, human capital ROI is a fundamental measurement of employee contribution. But what exactly is the definition of Human capital ROI? How do you calculate it, and why should you use this metric? Let’s dive in.

What is human capital?

Human capital (HC) is an intangible asset that is a sum of the economic value of employees’ experience and skills. The ‘capital,’ in this instance, refers to assets such as knowledge, skills, health, education, etc. There is a distinct difference between human resources and human capital. 

Resources often imply that it is a finite source or that it can be exploited (the term has also been associated with materials, manufacturing, etc.). This is obviously not the way ‘human resources’ is seen. However, the association tends to strongly imply the above meaning. On the other hand, human capital implies, for example, wealth that can be invested in. Talentalign created this diagram which shows the various aspects of HR and HC. It illustrates how they are similar but also differ:


What is human capital ROI?

Human capital ROI (HCROI) is a strategic HR metric that reflects the financial value added by the workforce as a result of the money spent on employees (in terms of recruiting, employee compensation, talent management, training, etc.). It shows the value that employees contribute individually or collectively. The metric is a true reflection of the value of the human capital in an organization.

GrowthForce shows an example of HCROI:


The human capital ROI formula

Calculating the return on investment for human capital is complex. It requires you to allocate a financial benefit to a human capital initiative. This is not always as straightforward because how do you actually know that, for example, a learning intervention directly contributed towards an increase in revenue? There are so many variables that could affect the outcome, including market volatility, change in conditions, and even luck. The ROI Institute, however, developed a model that is able to accurately calculate HCROI. Let’s break it down:


Let’s break down each of the main steps: 

  • Evaluation planning – This is the part to clearly define the objectives of your human capital initiative. For example: “Hire three IT network developers” or “Implement a talent exchange program in the marketing department” or “Achieve an Employee Net Promoter Score of +20”. 
  • Data collection – This is the collection of data pre, during, and after implementing an HC program or action. During this period, you may collect human capital metrics: hard data (which you can do via HC systems) and soft data (which you can gather in employee satisfaction surveys, on-the-job observation, etc.).
  • Data analysis – To calculate the ROI of human capital, this is one of the most important steps. You need to analyze data on two fronts:
    • Isolate the effects of the HC initiative or program – This is important because many factors can influence performance, and you want to specifically measure the impact of human capital. There are many ways to do this, including launching a pilot program, using trend lines to show differences, customer input, external stakeholder feedback, and using subject matter experts to analyze effects. 
    • Convert HC data to financial output – This requires the cost of every human capital program to be accounted for and given a value. This is situation-dependent. As an example, due to a training program, an employee might develop an additional product. That additional product is thus converted to a profit or cost-saving, depending on the initiative’s outcome.

Once you have followed the above steps, you will have enough information to calculate the financial return with this formula:


Human capital ROI calculation examples

Let’s use this formula in a few examples of human capital ROI calculation.

Suppose you roll out a health and wellness initiative in the workplace, costing approximately $250,000. Those are your human capital expenses. The savings (reduction in stress, absenteeism, burnout, etc.) you made from this initiative amounts to $750,000. Therefore:

HCROI = ($750,000 – $250,000)/$250,000

             = 2 (represented as a ratio 2:1)

This means that for every $1 you spent on the wellness program, there was a benefit of $2. There are variables you need to consider, of course, when analyzing things in this way (for example, the measurement period of the cost-saving). As long as the data and time frame are consistent, this is a highly effective way to calculate HCROI. 

Now, let’s say the team decides to invest an additional $10,000 in the program, but it results in an additional saving of $150,000. Your formula would look like this:

HCROI = $900,000 – $260,000/$260,000

= 2.46 or represented as a ratio (2.46:1)

So, for only investing an additional $10,000, that’s an additional benefit of 0.46. Over a long period of time, the value saved is almost insurmountable. Using these formulas is a great way of planning and reflecting. You’re able to see the long-term effects that investing a little bit more into your human capital can have on the financial performance of the organization.

Benefits of using the human capital ROI as a metric and KPI

  • Understanding the impact of your human capital initiatives. You can see what results your initiatives bring. That way, all your decisions are data-based, and every dollar spent can be accounted for.
  • Showing tangible results of HC initiatives to the leadership. Essentially, you’re able to quantify the business impact of your efforts and show it to the leadership. For example, you’re able to directly translate the results of HC initiatives such as a “talent exchange program” to the financial impact on the business. 
  • Identifying and filling the gaps in human capital. The data helps you understand where your organization is excelling and where it lacks in terms of human capital. You’re able to clearly see through data what adding or subtracting human capital will have on the business outcome. 
  • Improve your HC processes. Through a variety of feedback mechanisms received as a result of calculating ROI, you’re able to improve your human capital management practices and processes. Along the way, you’re able to make adjustments (in real-time as well) and understand specifically which part of the HC process needs improvements.
  • Eliminate ineffective HC processes. You’re also able to close or remove any human capital initiatives that are not effective. If, for example, a talent exchange program is yielding no financial benefits after five years, you’re able to close the program or make adjustments along the way. Either way, you’re able to cut down on costs.

A final word

If you want to measure the tangible impact of your HC efforts, regularly calculating the human capital ROI will be very beneficial. Based on the results, you’ll be able to gain new insights, see opportunities for improvement and bring your HC initiatives to the next level.

https://www.aihr.com/blog/human-capital-roi/

Measuring the return on human capital
Smita Anand, TNN 
The goal for a business is simple: Invest capital so that it maximises shareholder value. But, not so simple are the actions that are needed for a business to achieve this goal.
Successful strategy execution depends on access to intellectual and operational knowhow, customer and supplier relationships, a committed workforce, and other such intangibles. At the heart of making these intangibles come-alive is the firm's investment in human capital.
Capital budgeting and financial planning frameworks offer very little to guide human capital investment decisions; yet manpower costs typically constitute a significant component of operating expenses. However, it is possible to calculate return on human capital with factual analysis, which, in turn, can help develop insights into human capital management and generate sustainable economic returns.
The critical thing is to track critical employees. Our research demonstrates that the flow of pivotal employees in and out of an organisation is a strong predictor of change in CFROI® (Cash Flow Return on Investment).
Talent Quotient (TQ™) is a measure of a company's ability to attract and retain critical employees — those who may be thought of as pivotal to business success. TQ measures two key components, (i) the proportion of pivotal employees joining an organisation as a ratio of all new hires in a given period (TQ-Attract) and, (ii) the proportion of pivotal employees leaving the organisation as a ratio of all employees leaving over a given period (TQ-Retain).
Few organisations understand their employee investments beyond the cost of salary and benefits and fewer still understand the return on their investment in employees. The fact remains that most firms lack a basis for structuring or prioritising human capital investments, and a concrete notion of what return on investment is generated over time.
There are many ways to do it. Let us take a look at a potential area of application, i.e. measuring ROI on talent retention strategies implemented by an organisation.
Measuring ROI on these strategies (e.g. long term incentives, compensation increases, etc.) could appear to be complex, but it actually is a simple task if one de-constructs the key elements that need to be tracked and correlated.
Let us assume that for our purposes 'critical talent' is those employees who are in the top 25% on performance. This would likely translate into these employees also being the top 25% on compensation increases for the time period (this is the investment made by an organisation). The objective should be to ensure that the organisation is able to retain this group of employees better than the rest of the employee population within the organisation (because it has invested more in this segment).
Thus, a way to measure this in a quantifiable manner could be: ROI on talent retention = 1 – (attrition rate of critical talent/attrition rate of all employees). In a market that is constantly witnessing an upsurge in salaries and shortage of skilled workforce, such measurement would enable organisations to invest in human capital in a focused manner. There are other similar simple constructs that explore the viability of talent attraction and other retention investments. The next logical step would be to establish benchmarks and develop predictive tools to help guide organisations make the right investment decisions.
If one were to look beyond the technicalities of any one particular approach, the basic need is for organisations to apply rigor in calculating the returns on the multi-million dollar investments they make each year in their employees and the ways in which they can do so.
Companies need to measure the value that employees bring to the organisation, evaluate their impact on business performance and then align them with the business results. Companies have always measured their investments in more tangible assets such as buildings, equipment and even new products. Why should talent be far behind?

пятница, 29 августа 2014 г.

The Six Disciplines Entrepreneurs Need To Succeed

(Photo credit: Wikipedia)


When starting out in business, you may be able to fumble your way to short-term success if you have a good product and a measure of business savvy. If you want to experience long-term success, however, there are some core disciplines that must be learned and executed. At some point (sooner is better than later), you will need to become skilled in the following six areas:
1. Conducting Market Research: Doing market research will provide you with key information about the industry in which you operate. It will also help you develop your business plan and adapt it over time. Adequate market research includes, at a minimum, the following areas:
  • Industry: Trends, main competition, growth rates, sales figures
  • Competition: Profile your competitors; examine the good and bad points about their operations
  • Ideal Customers: Their demographics, geographic locations, typical profile
2. Testing Your Ideas: Starting a new business or launching a new product can be intimidating, but it’s also very exciting. Sometimes the excitement causes entrepreneurs to over-commit time and resources on untested or unproven ideas. This is a recipe for failure.
Find ways to test every idea before rolling it out. With the Internet, testing an idea does not have to be difficult or expensive. Search engines and social networks provide some incredible tools that can be used to effectively test and perfect business ideas.
3. Developing Business Plans: Another important discipline involves proper planning. Creating a business plan in the beginning will raise your likelihood of future success because it forces you to think about and plan for critical issues you will face down the road. Furthermore, by devoting time to planning each year, you will be better equipped to adapt to changing market conditions.
There are several mobile and desktop applications that make creating business plans much simpler than it used to be.
4. Saving vs. Spending: It’s easy to spend money on a new venture, and many entrepreneurs overspend in the beginning. Because it can take a while to get established and begin generating revenue on a consistent basis, it is wise to maintain a cushion at all times. A new business owner should have at least six months of operating costs socked away before going into business.
5. The Art of Negotiating: Knowing how to negotiate is one of the most powerful skills an entrepreneur can acquire. When opportunities arise, you must know how to negotiate for lower prices when buying and higher prices when selling. If negotiating is not one of your strengths, study the art of negotiating and practice doing it whenever you get the chance.
6. Mental Toughness: If you’re not resilient, you won’t be able to bounce back from the setbacks that you will face. Every entrepreneur inevitably faces setbacks and failures. Some will be small, and some will be so big that they will seem overwhelming. You must cultivate mental toughness and the determination to press on despite obstacles if you’re going to survive in the business world.
Last Word
You have the ability to build a successful business. Thousands of people have done it who have no more ability than you do. To succeed, they simply learned the necessary behaviors to make their dreams a reality, and consistently took action to reach their goals. You can do the same.

Courtesy of YEC
Robert Sofia is a best-selling author, award winning public speaker, and financial industry thought leader. He is the cofounder and C.O.O of Platinum Advisor Strategies - ranked #362 on the INC 5,000 list of America’s fastest growing privately owned companies, and #10 on the Agency 100 list of the nation’s fastest growing agencies.

четверг, 7 августа 2014 г.

Top 25 Pharma and Biopharma Report

Big Pharma continues to face the impact of competitive pressures, fluctuating currencies, the patent cliff, and pipeline surprises, all of which were reflected in financial results last year.



Published July 21, 2014

Payers around the world are demanding lower cost drugs and increased access to medicines, while stakeholders look for higher returns on their investment.

Mergers and acquisitions, particularly those involving an offshore partner, continue to be seen, both as an easier way to augment a pipeline and as a tax-saving strategy, even though Pfizer’s $119-billion bid for AstraZeneca this Spring was rebuffed and Shire has also rejected AbbVie’s offers this Summer.

Divestments and increased focus on core markets were the themes last year, and we can continue to see them play out in the future. Both Novartis and Pfizer unloaded their animal health care businesses to focus on human therapeutics.

Companies are investing in developing economies and in biopharma, and forming strategic alliances, often with competitors, to achieve their goals. Exemplifying the trend was April’s business swap between Novartis and GSK, in which the companies traded vaccines and oncology businesses, and also built a new jointly owned consumer healthcare venture.

Novartis came in as number one, because its generics and vaccine manufacturing business totals were included, for parity with other manufacturers where these businesses were considered in the total. Clearly, biopharmaceutical products play an increasingly pivotal role in Big Pharma’s drug pipelines. For example, Pfizer, which narrowly trailed Novartis as player Number Two this year, reports that biopharmaceuticals contributed 93% of its total revenues last year (94% of that figure in 2012 and 95% in 2011). 

Generics are becoming increasingly important, and, even before clear and harmonized global regulations take shape, companies are developing biosimilars pipelines. There is also a trend to investing in over-the-counter (OTC) markets, as more of yesteryear’s blockbusters are expected to be available directly to the consumer in the near future.

In response to these changing realities, we have expanded our list slightly this year, to include pharma and biopharma companies, consumer healthcare divisions, and generics firms.Here is a quick look at key financial results. Some figures reported last year were adjusted in this year’s annual reports. This report is a very broad brush stroke view of trends, news and strategies based on developments this and last year.  We hope that you find it useful.

Top 25 Pharma and Biopharma Companies (Based on 2013 Sales, in $U.S. Millions)
1.Novartis$57,920
2.Pfizer$51,584
3.Sanofi$45,360
4.Merck & Co.$44,033
5.Roche$43,560
6.GSK $41,613
7.J&J$28,125
8.AstraZeneca $25,711
9.Eli Lilly $23,113
10.Teva$20,314
11.Boehringer-Ingelheim$19,362
12.AbbVie$18,790
13.Amgen$18,676
14.Bristol-Myers Squibb$16,385
15.Takeda$16,075
16.Novo Nordisk$15,422
17.Bayer $15,401
18.Merck Serono $15,273
19.Gilead Sciences$11,201
20.Astellas$11,086
21.Daiichi Sankyo $10,881
22.Actavis$8,678
23.Mylan$6,909
24.Biogen Idec $6,932
25.Baxter $6,564